Osteosarcoma is characterised by reduced expression of markers of osteoclastogenesis and antigen presentation compared with normal bone
about
A novel androstenedione derivative induces ROS-mediated autophagy and attenuates drug resistance in osteosarcoma by inhibiting macrophage migration inhibitory factor (MIF).Different expression of alternative lengthening of telomere (ALT)-associated proteins/mRNAs in osteosarcoma cell lines.Auranofin is a potent suppressor of osteosarcoma metastasis.MiR-367 negatively regulates apoptosis induced by adriamycin in osteosarcoma cells by targeting KLF4.Serum metallothioneins in childhood tumours-a potential prognostic marker.Pivotal regulatory network and genes in osteosarcomamiR-22 promotes apoptosis of osteosarcoma cells via inducing cell cycle arrest.MicroRNA-21 promotes proliferation, invasion and suppresses apoptosis in human osteosarcoma line MG63 through PTEN/Akt pathway.Zinc chelation: a metallothionein 2A's mechanism of action involved in osteosarcoma cell death and chemotherapy resistance.Osteopontin: its potential role in cancer of children and young adults.Screening of candidate key genes associated with human osteosarcoma using bioinformatics analysisIdentification of characteristic gene modules of osteosarcoma using bioinformatics analysis indicates the possible molecular pathogenesis.MEG3 inhibits proliferation and invasion and promotes apoptosis of human osteosarcoma cells.Exploring the key genes and pathways of side population cells in human osteosarcoma using gene expression array analysis.MiR-92a Inhibits the Progress of Osteosarcoma Cells and Increases the Cisplatin Sensitivity by Targeting Notch1.Targeting a novel bone degradation pathway in primary bone cancer by inactivation of the collagen receptor uPARAP/Endo180HSP90AA1-mediated autophagy promotes drug resistance in osteosarcomaThe roles of metallothioneins in carcinogenesisBMP-2 inhibits lung metastasis of osteosarcoma: an early investigation using an orthotopic model
P2860
Q35679492-D6357BAC-B68C-40A7-B956-90003F85731DQ36121451-6C3EF9EB-B3D7-4905-8710-ADCEC7135237Q36729542-269E654D-C5CF-4B23-8E3A-C9CB6C821D20Q37005083-5E935044-9F28-47E1-B904-0A5B12DEC700Q37007306-7FB79A32-80C3-422B-ADBD-ECF2C4E286A5Q38488094-C3B7DE72-7F66-4B03-936F-1D8CF4F1E3C7Q38705618-55DA2D7A-1BBC-4834-9C62-D1AED7343FE8Q38802466-A65CE8D3-11B9-465F-810C-9A9BE1297511Q39070928-67E26715-9448-4A2B-9F1D-BEBD507D7410Q39192350-22B75BAF-F9E4-48D1-9414-C91C57E729C9Q41611482-F2BDF757-7B9B-4633-B2D0-3434DF0292BCQ42314416-C81540AE-E6A1-4B10-9B8D-8C71FD9E0621Q49419404-FB5F05C0-8867-4D7F-974E-FA373ACBF19CQ55443020-9FC7A980-1CAC-4C60-8589-A981C6828F5CQ55492687-8D90D033-38F7-42F4-A219-27E0DCEC9B6BQ57680380-A95A6EAA-EEE7-43E3-85F0-EF1560CD10C3Q58698951-A7FB0F64-D1EA-4CDB-807B-D31F88084878Q58713688-043A5BCB-6E59-47EE-800D-4EFA511C2522Q59135256-9E4311CA-8F87-4384-9A4E-ABB49AC7E46E
P2860
Osteosarcoma is characterised by reduced expression of markers of osteoclastogenesis and antigen presentation compared with normal bone
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Osteosarcoma is characterised ...... tion compared with normal bone
@ast
Osteosarcoma is characterised ...... tion compared with normal bone
@en
Osteosarcoma is characterised ...... tion compared with normal bone
@nl
type
label
Osteosarcoma is characterised ...... tion compared with normal bone
@ast
Osteosarcoma is characterised ...... tion compared with normal bone
@en
Osteosarcoma is characterised ...... tion compared with normal bone
@nl
prefLabel
Osteosarcoma is characterised ...... tion compared with normal bone
@ast
Osteosarcoma is characterised ...... tion compared with normal bone
@en
Osteosarcoma is characterised ...... tion compared with normal bone
@nl
P2093
P2860
P356
P1476
Osteosarcoma is characterised ...... tion compared with normal bone
@en
P2093
I Dickinson
S Sommerville
P2860
P2888
P356
10.1038/SJ.BJC.6605723
P407
P577
2010-06-15T00:00:00Z
P5875
P6179
1021570459